9月15日 - ** 药物开发商BioVie（BIVI.O）的股价在盘前交易中下跌10.7%，至1.83美元
** 该公司表示，其试验性口服药物bezisterim在一项涉及203名长期新冠患者的中期临床试验中，在22项评估指标中均未达到统计学显著性
** 长新冠可能导致初次感染新冠后症状持续存在，包括疲劳、思维困难、睡眠问题以及在进行体力或脑力活动后症状加剧
** 在21项评估指标中，该药物表现优于对照组，但显著疗效仅限于预先指定的亚组，即疲劳更严重、思维障碍更明显或活动后症状加重的患者——BIVI
** 这些亚组患者约占试验参与者的78%；该公司表示，亚组研究结果仅为探索性发现，尚需通过更大规模的后期临床试验予以验证
** 安全性与安慰剂相当，接受贝西斯特林治疗的患者中未报告严重副作用
** 截至上一交易日收盘，BIVI今年以来累计上涨76.7%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.